10-K: Lexaria Bioscience Reports Soaring Losses Amid R&D Push

Lexaria Bioscience Corp. reported a significant increase in net losses for fiscal year 2025, driven by substantial investments in DehydraTECH R&D for diabetes, weight loss, and hypertension treatments, while facing going concern doubts.

Summary

• Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients (APIs) using its patented DehydraTECH drug delivery technology.
• The company's primary R&D focus is on GLP-1/GIP drugs for diabetes and weight loss, and cannabidiol (CBD) for hypertension.
• Lexaria was granted 6 new patents in fiscal year 2025, expanding its global patent portfolio to 56, including 22 in the US.
• Net loss increased by $6.1 million to $11.9 million for the fiscal year ended August 31, 2025, compared to $5.8 million in the prior year.
• Research and development expenses surged by 249% to $8.2 million in fiscal year 2025.
• Revenue increased by 52% to $705,923 in fiscal year 2025, primarily from IP licensing.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash to meet operational requirements for the next 12 months.
• Completed several human pilot and animal studies for DehydraTECH-enhanced GLP-1/GIP drugs and CBD, showing promising results in reducing adverse events and improving drug delivery characteristics.
• Received a 'Study May Proceed' letter from the FDA for its Phase 1b Investigational New Drug (IND) trial of DehydraTECH-CBD for the reduction of hypertension, pursuing a faster 505(b)(2) regulatory pathway.

Sentiment

Score: 3

Explanation: While the company shows promising R&D results and patent growth, the significant increase in net loss, substantial doubt about going concern, and continuous need for capital raises indicate a challenging financial position. The positive scientific advancements are overshadowed by the financial instability and operational risks.

Positives

• Granted 6 new patents in fiscal year 2025, including for GLP-1/GIP drugs, epilepsy, sublingual nicotine, and food products, expanding intellectual property protection.
• DehydraTECH-semaglutide and DehydraTECH-tirzepatide demonstrated a 43.5% and 56.5% reduction in gastrointestinal adverse events, respectively, compared to the Rybelsus control arm in a chronic human study (GLP-1-H24-4).
• Orally delivered DehydraTECH-tirzepatide produced fewer adverse events and reached blood level parity with injectable Zepbound by the end of a 7-day human pilot study (GLP-1-H24-3).
• Orally delivered DehydraTECH-liraglutide showed comparable blood glucose, insulin, and body weight-control measurements to injectable Saxenda with fewer adverse events in human pilot study GLP-1-H25-5.
• A rodent biodistribution study suggested DehydraTECH-semaglutide demonstrated a predominantly higher apparent trend in brain biodistribution compared to a Rybelsus mimicking formulation.
• The FDA agreed to a 505(b)(2) new drug application (NDA) regulatory pathway for DehydraTECH-CBD for hypertension, potentially enabling a quicker route to commercial approval.
• The FDA determined no additional non-clinical studies are needed before the start of the IND program for DehydraTECH-CBD for hypertension.
• Licensing revenue grew by $238,010, or 52%, to $696,000 in fiscal year 2025.

Negatives

• Net loss increased significantly by $6.1 million to $11.9 million in fiscal year 2025.
• Research and development expenses surged by $5.9 million, or 249%, to $8.2 million in fiscal year 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash ($1.8 million cash vs. $1.5 million current liabilities as of August 31, 2025) to fund expected expenditures for the next 12 months.
• Revenue from technology licensing of DehydraTECH processed hemp-based CBD and other consumer products is expected to decrease in fiscal 2026 due to the expiration of the Premier license agreement.
• An impairment loss of $247,364 was recognized on intellectual property, related to abandoned patent applications and a write-down of the patent portfolio.
• The WEIGHT-A24-1 animal study experienced a lack of detectable semaglutide and liraglutide levels in most treatment groups, suspected to be due to an undetermined analytical detection issue.
• Hill Incorporated, a licensee for cannabis products, made an assignment in bankruptcy on November 21, 2025, impacting a note receivable and marketable securities held by Lexaria.
• Marketable securities (Hill Inc. common shares) experienced unrealized losses of $33,714 in fiscal year 2025.

Risks

• DehydraTECH-enabled pharmaceutical products may not successfully proceed to commercialization due to potential setbacks in advanced clinical trials, such as lack of efficacy or adverse safety profiles.
• Inability to retain and hire qualified personnel, especially key research, product development, regulatory, and technical staff, could hinder business plan implementation.
• Substantial competition from major multinational pharmaceutical companies, established biotechnology companies, and early-stage companies with greater financial, technical, and other resources.
• Failure to protect intellectual property, as patent applications may not be granted, or issued patents may be challenged, invalidated, or circumvented.
• Technological R&D in the bioscience industry is a lengthy, expensive process with uncertain outcomes, potentially leading to additional costs, delays, or abandonment of studies or trials.
• Dependence on third parties to conduct, supervise, and monitor R&D programs and for manufacturing, with risks of unsatisfactory performance, missed deadlines, or non-compliance.
• Security breaches and improper access to or disclosure of company or user data could harm business, reputation, and competitive position.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets.
• Substantial doubt about the company's ability to continue as a going concern, which may affect its ability to obtain future financing.
• Inability to secure future equity or debt financing on acceptable terms, leading to potential reduction in spending, curtailment of programs, or liquidation of assets.
• The longer-term growth of the business depends on expanding the patent portfolio and industry segments, which may require substantial financial resources and may ultimately be unsuccessful.
• Failure to enter into successful collaborations with third parties for development and commercialization could limit the market potential of product candidates.
• Product candidates are in early stages of development and may fail or experience significant delays, or never advance to the clinical stage.
• Pharmaceutical products incorporating DehydraTECH have never been approved for the treatment of disease, and obtaining regulatory approval is an expensive, multi-year, and uncertain process.
• Limited FDA approval for CBD as an API for disease treatment, and evolving, non-harmonious regulation of non-pharmaceutical hemp-based CBD products.
• Controlled substance legislation differs between localities, potentially restricting or limiting the ability to develop and commercialize products using DehydraTECH.
• The trading price of the company's common stock could be highly volatile, leading to substantial losses for investors.
• The company's by-laws do not contain anti-takeover provisions, which could result in a change of executive management and directors.
• The company does not intend to pay any dividends on its shares, meaning investors will rely solely on stock price appreciation for returns.
• Purchasers of shares may incur dilution from future equity capital raises.
• Operating as a smaller reporting company and non-accelerated filer may make common shares less attractive to investors due to reduced disclosure and lack of auditor attestation requirements.

Future Outlook

Lexaria Bioscience Corp. expects to continue incurring significant operational expenses and net losses in the upcoming 12 months and beyond, with R&D expenses anticipated to decrease in 2026 unless corporate financing activities are successful. The company aims to form industry partnerships for later-stage clinical development and will require substantial further funding to complete the full development, testing, and commercialization of an FDA-approved product candidate. Revenue from technology licensing of hemp-based CBD products is expected to decrease in fiscal 2026 due to an expired license agreement, but the company anticipates strengthening revenue prospects through intellectual property expansion and new R&D applications.

Management Comments

• We are extremely pleased with these initial results [reduction of GI adverse events in GLP-1/GIP studies].
• We remain confident that the loss [on Hill Inc. marketable securities] may be temporary in nature as Hill Inc. continues to make inroads into the US hemp markets with DehydraTECH enabled products produced and sold by their licensees.
• We believe there are meaningful competitive advantages in manufacturers adopting DehydraTECH in their products, including its demonstrated higher absorption levels, its ability to infuse smaller quantities of active molecules in their products and the benefit of its predictable drug delivery times.
• Implementing our technology could lead to smaller dosing and decreased manufacturing costs while masking unwanted flavor and smell of the active molecules.
• We are anticipating these efforts will lead to increased licensing revenue through licensing partnerships.
• Lexaria has concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet our operational requirements for the twelve months following the release of these audited financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern for at least one year following the date of the consolidated financial statements included in this report.

Industry Context

The filing highlights the significant market potential for GLP-1 drugs in diabetes and weight loss, with the anti-obesity market projected to reach $100 billion by 2030, and the oral market share at $25 billion. It also notes the global burden of hypertension, affecting 1.3 billion people, with a treatment-resistant hypertension market expected to reach $159.4 million by 2033. Lexaria positions its DehydraTECH technology to address side effects and improve efficacy in these large markets, particularly for oral GLP-1/GIP drugs and CBD for hypertension, where current treatments may have limitations or significant side effects.

Comparison to Industry Standards

• DehydraTECH-semaglutide and DehydraTECH-tirzepatide showed a 43.5% and 56.5% reduction in gastrointestinal adverse events, respectively, compared to commercially available Rybelsus.
• Orally delivered DehydraTECH-tirzepatide produced fewer adverse events compared to injected Zepbound (Eli Lilly) and reached blood level parity by the end of a 7-day study.
• Orally delivered DehydraTECH-liraglutide produced fewer adverse events and comparable blood glucose, insulin, and body weight-control measurements compared to commercially available injectable Saxenda.
• DehydraTECH delivered higher volumes of CBD into the human circulatory system more quickly than a concentration-matched positive control in a 2019 study.
• DehydraTECH-CBD demonstrated a statistically significant reduction in human blood pressure compared to no statistical reduction from the positive control in a 2019 study.

Management Changes

Corporate Governance

Legal Proceedings

• Richard Christopher, the current CEO and a director, was formerly the Chief Financial Officer of InVivo Therapeutics Corporation, which filed for Chapter 11 bankruptcy on February 1, 2024, following a failed clinical trial. The court ordered distributions to equity security interests on November 18, 2025.

Related Party Transactions

• Lexaria Nicotine LLC, a subsidiary, is 16.667% owned by Altria Ventures Inc. (an indirect wholly owned subsidiary of Altria Group, Inc.).
• Lexaria CanPharm ULC holds a promissory note payable by Hill Inc. with an original value of CDN$2 million and 10% annual interest, which is reduced quarterly by 5% royalty payments. The note was recorded at a zero value due to high doubt of repayment.
• The company holds 242,880 shares of Hill Inc. common stock, with a carrying value of $22,093 as of August 31, 2025.
• Hill Incorporated, a licensee for cannabis products, made an assignment in bankruptcy on November 21, 2025, impacting the note receivable and marketable securities.

Stakeholder Impact

• Shareholders face significant dilution from ongoing equity raises, potential for further dilution, substantial doubt about the company's ability to continue as a going concern, erratic share price volatility, and no expected dividends, leading to a high risk of investment loss.
• Employees and management benefit from equity incentive plan participation and increased stock-based compensation, but face potential job insecurity if adequate funding is not secured.
• Licensees benefit from DehydraTECH's enhanced performance, but face risks related to Lexaria's financial instability potentially impacting support or continued R&D. The bankruptcy of Hill Inc. directly impacts one licensee relationship.
• Creditors face elevated risk due to the company's recurring losses and the substantial doubt about its ability to continue as a going concern.

Next Steps

• Complete full sample and data analyses for the GLP-1-H24-4 chronic human study, with a final reporting objective of late calendar-2025.
• Report pharmacokinetic results from human pilot study GLP-1-H25-5 (liraglutide) once available.
• Address FDA conditions and seek funding to commence the Phase 1b IND trial HYPER-H23-1 for DehydraTECH-CBD for hypertension.
• Continue to explore accelerated timetable options for testing, research, and further development of R&D programs.
• Pursue new R&D programs investigating potential commercial applications for DehydraTECH.
• Continue to investigate national and international opportunities to pursue expansions and additions to the intellectual property portfolio.
• Explore equity financing arrangements and strategic corporate business partnerships for specific drug investigations.
• Continue to pursue license arrangements in multiple bioactive ingredient sectors identified in issued and pending patent applications.
• Assess the impact of Hill Incorporated's bankruptcy filing on its licensing arrangement.

Key Dates

Recommendation

Despite promising R&D results for DehydraTECH, the company's financial position is highly precarious, with a substantial doubt about its ability to continue as a going concern. The significant increase in net losses, heavy reliance on continuous equity financing leading to dilution, and the bankruptcy of a key licensee (Hill Inc.) present severe financial risks. While the technology has potential, the current financial instability and the need for substantial future funding make the stock a high-risk investment with a strong likelihood of further capital erosion for existing shareholders.

Keywords

DehydraTECH, drug delivery, bioavailability, GLP-1, GIP, semaglutide, tirzepatide, liraglutide, CBD, cannabidiol, hypertension, diabetes, weight loss, biotechnology, pharmaceuticals, patents, R&D, SEC filing, 10-K, Nasdaq